Literature DB >> 23109446

Greater Celandine hepatotoxicity: a clinical review.

Rolf Teschke1, Christian Frenzel, Xaver Glass, Johannes Schulze, Axel Eickhoff.   

Abstract

Herbal hepatotoxicity is a rare and poorly described disease because reported cases are mostly scattered and lack an appropriate causality assessment. We now describe in detail the clinical picture of herbal hepatotoxicity by extracts of Greater Celandine (GC), syn. Chelidonium majus L. from the Papaveraceae family, which contain more than 20 ingredients including various biologically active isoquinoline alkaloids. For this purpose, we analyzed and reviewed published cases of 16 patients from various European countries. In all patients, herbal hepatotoxicity was of probable and highly probable causality for GC, using the original and updated scale of CIOMS (Council for International Organizations of Medical Sciences). GC associated hepatotoxicity usually has an acute clinical course exhibiting a hepatocellular pattern of injury and is correlated to an idiosyncratic reaction with its metabolic subtype. Jaundice combined with high values of serum aminotransferases was present in virtually all cases with favourable outcome despite severe clinical course. In conclusion, GC hepatotoxicity is a typical herbal hepatotoxicity with a sound causality track for GC, but there is uncertainty regarding the respective causative compound(s). The present detailed review of GC hepatotoxicity may serve as an example for clinical causality assessments of future cases of liver injury due to other herbs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109446

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  14 in total

1.  Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation.

Authors:  Esteban Sáez-González; Isabel Conde; Francia Carolina Díaz-Jaime; Salvador Benlloch; Martín Prieto; Marina Berenguer
Journal:  Am J Gastroenterol       Date:  2016-09       Impact factor: 10.864

Review 2.  Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs.

Authors:  Rolf Teschke; Dominique Larrey; Dieter Melchart; Gaby Danan
Journal:  Medicines (Basel)       Date:  2016-07-19

Review 3.  Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Alexander Schwarzenboeck; Johannes Schulze; Axel Eickhoff
Journal:  World J Hepatol       Date:  2014-01-27

Review 4.  Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods.

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

Review 5.  Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps.

Authors:  Rolf Teschke; Axel Eickhoff
Journal:  Front Pharmacol       Date:  2015-04-23       Impact factor: 5.810

Review 6.  RUCAM in Drug and Herb Induced Liver Injury: The Update.

Authors:  Gaby Danan; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

7.  Mining Adverse Events of Dietary Supplements from Product Labels by Topic Modeling.

Authors:  Yefeng Wang; Divya R Gunashekar; Terrence J Adam; Rui Zhang
Journal:  Stud Health Technol Inform       Date:  2017

Review 8.  Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Drug Saf       Date:  2016-08       Impact factor: 5.228

Review 9.  Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation.

Authors:  Christian Frenzel; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

Review 10.  Hepatotoxicity of Herbal Supplements Mediated by Modulation of Cytochrome P450.

Authors:  Christopher Trent Brewer; Taosheng Chen
Journal:  Int J Mol Sci       Date:  2017-11-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.